Cansu Barış Moğul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cansu Barış Moğul has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bürge Kabukçu Başay
Pamukkale University
1 shared publication - Hande Şenol
Department of Biostatistics, Pamukkale University School of Medicine, Denizli, Turkey
1 shared publication - Nilay Şen Türk
Pamukkale University
1 shared publication - Sibel Hacıoğlu
Department of Hematology, Pamukkale University Faculty of Medicine, Denizli, Turkey
1 shared publication - Vildan Caner
Pamukkale University
1 shared publication - Yavuz Dodurga
Department of Medical Biology, Pamukkale University, Denizli, Turkey
1 shared publication
Latest Publications
- 5 October 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 204, 49-56
Altered toll-like receptor expression in autism spectrum disorder: Evidence from mRNA and serum protein analyses
- 5 October 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 204, 49-56
Altered toll-like receptor expression in autism spectrum disorder: Evidence from mRNA and serum protein analyses
- 30 September 2025
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 9 (3) , 593-603
Circulating Exosomal CD30 And CD79B in Diffuse Large B-Cell Lymphoma Patients
Purpose: Up to 30-40% of patients do not respond to treatment or relapse after R-CHOP chemoimmunotherapy in DLBCL. The predictive biomarkers for identifying candidates for new therapies have not been extensively studied. We aimed to determine the presence of CD3, CD19, CD20, CD30 and CD79B in plasma-derived exosomes from DLBCL patients and to compare the profiles of target proteins in exosomes and matched primary tumour tissue. Material and Methods: Exosome samples from 20 newly diagnosed DLBCL patients and 20 healthy controls from our previous studies were characterized according to the recent MISEV2018 guidelines. The presence of targeted antibodies in exosomes was determined by Western Blotting, while their expression in primary tumour tissue was analysed by immunohistochemistry. Results: Seventeen (85%) patients had CD30-positive exosomes in their blood, while tumor cells expressing CD30 were found in only 2 (10%) patients. We only evaluated CD79B expression in tumor cells from 6 patients. Conclusion: In addition to tumor cells, characterising the factors present in the tumor microenvironment that support tumor cells, such as exosomes, will increase our success in treating DLBCL. Preclinical and clinical studies are needed to evaluate the presence of circulating CD30- and CD79B-positive exosomes in the selection of candidates for targeted immunotherapies using a non-invasive approach.
- 30 September 2025
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 9 (3) , 593-603
Circulating Exosomal CD30 And CD79B in Diffuse Large B-Cell Lymphoma Patients
Purpose: Up to 30-40% of patients do not respond to treatment or relapse after R-CHOP chemoimmunotherapy in DLBCL. The predictive biomarkers for identifying candidates for new therapies have not been extensively studied. We aimed to determine the presence of CD3, CD19, CD20, CD30 and CD79B in plasma-derived exosomes from DLBCL patients and to compare the profiles of target proteins in exosomes and matched primary tumour tissue. Material and Methods: Exosome samples from 20 newly diagnosed DLBCL patients and 20 healthy controls from our previous studies were characterized according to the recent MISEV2018 guidelines. The presence of targeted antibodies in exosomes was determined by Western Blotting, while their expression in primary tumour tissue was analysed by immunohistochemistry. Results: Seventeen (85%) patients had CD30-positive exosomes in their blood, while tumor cells expressing CD30 were found in only 2 (10%) patients. We only evaluated CD79B expression in tumor cells from 6 patients. Conclusion: In addition to tumor cells, characterising the factors present in the tumor microenvironment that support tumor cells, such as exosomes, will increase our success in treating DLBCL. Preclinical and clinical studies are needed to evaluate the presence of circulating CD30- and CD79B-positive exosomes in the selection of candidates for targeted immunotherapies using a non-invasive approach.